Hutchmed (China) Limited (HCM) ORD USD0.10
4.00p
(1.83%)
- Add to watchlist
- Create an alert
- This stock can be held in a
4.00p
(1.83%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
4.00p
(1.83%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
207.00p
219.00p
292.00p
£1.88 bn
218.00p
207.00p
187.50p
73.69
1.00p (0.46%) Previous:
1.00p
5,063
n/a
1,500
Performance
Not available for this stock.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue ($m) | 630.20 | 838.00 |
| Profit before tax ($m) | (1.11) | 58.31 |
| Adjusted EPS (¢): | 4.00 | 12.00 |
| P/E ratio | 79.70 | 32.00 |
| PEG | n/a | n/a |
| EPS growth (%) | (67.00) | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Hutchmed launches development programme for next-gen therapy platform
17 December 2025 17:08
-
Hutchmed medicines get renewed, new reimbursement coverage in China
8 December 2025 11:50
-
Hutchmed enrols last patient in phase three lung cancer trial
5 November 2025 14:22
-
HUTCHMED to Announce 2025 Final Results
6 February 2026 08:30
-
Publication of Phase III Results in The Lancet
14 January 2026 07:00
-
Positive Topline Results of Phase III Trial
7 January 2026 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.